Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors

The focus of FDA's Cardiovascular & Renal Drugs Advisory Committee review of AstraZeneca's Atacand Feb. 24 will be narrowed to a discussion of concomitant use with angiotensin-converting enzyme inhibitors in treating congestive heart failure